239 related articles for article (PubMed ID: 34917077)
21. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
22. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine.
Tan H; Yu T; Liu C; Wang Y; Jing F; Ding Z; Liu J; Shi H
Cancer Med; 2022 Dec; 11(23):4656-4672. PubMed ID: 35593226
[TBL] [Abstract][Full Text] [Related]
23. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development.
Lu TL; Li CL; Gong YQ; Hou FT; Chen CW
World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406
[TBL] [Abstract][Full Text] [Related]
24. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
Front Genet; 2022; 13():853113. PubMed ID: 35734437
[No Abstract] [Full Text] [Related]
25. TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma.
Guo L; Li X; Liu R; Chen Y; Ren C; Du S
Cancer Med; 2020 Sep; 9(18):6694-6709. PubMed ID: 32700817
[TBL] [Abstract][Full Text] [Related]
26. Intratumoral immunoglobulin isotypes predict survival in lung adenocarcinoma subtypes.
Isaeva OI; Sharonov GV; Serebrovskaya EO; Turchaninova MA; Zaretsky AR; Shugay M; Chudakov DM
J Immunother Cancer; 2019 Oct; 7(1):279. PubMed ID: 31665076
[TBL] [Abstract][Full Text] [Related]
27. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.
Xu H; Zheng X; Zhang S; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):159. PubMed ID: 34872567
[TBL] [Abstract][Full Text] [Related]
28. The screening of immune-related biomarkers for prognosis of lung adenocarcinoma.
Liu Z; Sun D; Zhu Q; Liu X
Bioengineered; 2021 Dec; 12(1):1273-1285. PubMed ID: 33870858
[TBL] [Abstract][Full Text] [Related]
29. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
J Big Data; 2022; 9(1):92. PubMed ID: 35855914
[TBL] [Abstract][Full Text] [Related]
30. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X; Hu Z; Huang C; Chang J
Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949
[TBL] [Abstract][Full Text] [Related]
31. Identification of tumor antigens and immune subtypes of glioma for mRNA vaccine development.
Chen Z; Wang X; Yan Z; Zhang M
Cancer Med; 2022 Jul; 11(13):2711-2726. PubMed ID: 35285582
[TBL] [Abstract][Full Text] [Related]
32. Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients.
Liu J; Wu H; Gao Z; Lou M; Yuan K
Bioengineered; 2021 Dec; 12(1):4123-4135. PubMed ID: 34288805
[TBL] [Abstract][Full Text] [Related]
33. NPM1 Is a Prognostic Biomarker Involved in Immune Infiltration of Lung Adenocarcinoma and Associated With m6A Modification and Glycolysis.
Liu XS; Zhou LM; Yuan LL; Gao Y; Kui XY; Liu XY; Pei ZJ
Front Immunol; 2021; 12():724741. PubMed ID: 34335635
[TBL] [Abstract][Full Text] [Related]
34. Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma.
Mao S; Li Y; Lu Z; Che Y; Huang J; Lei Y; Wang Y; Wang X; Liu C; Zheng S; Li N; Li J; Sun N; He J
Cell Oncol (Dordr); 2020 Aug; 43(4):681-694. PubMed ID: 32462608
[TBL] [Abstract][Full Text] [Related]
35. Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma.
Wei S; Sun Q; Chen J; Li X; Hu Z
Front Genet; 2022; 13():1068112. PubMed ID: 36579327
[No Abstract] [Full Text] [Related]
36. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
[TBL] [Abstract][Full Text] [Related]
37.
Liu L; Wang C; Li S; Qu Y; Xue P; Ma Z; Zhang X; Bai H; Wang J
Front Immunol; 2021; 12():677169. PubMed ID: 34354701
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
39. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma.
Wu P; Zheng Y; Wang Y; Wang Y; Liang N
J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329
[TBL] [Abstract][Full Text] [Related]
40. Identification of a Five Autophagy Subtype-Related Gene Expression Pattern for Improving the Prognosis of Lung Adenocarcinoma.
Zhang MY; Huo C; Liu JY; Shi ZE; Zhang WD; Qu JJ; Yue YL; Qu YQ
Front Cell Dev Biol; 2021; 9():756911. PubMed ID: 34869345
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
